THE “BUYER’S EYES” ADVANTAGE
We have a long history of representing financial and strategic MedTech acquirers and understand that buyers may have vastly different perspectives and notions of value when looking at a business. Considering these varied perspectives enables us to achieve the best possible terms, strategic fit and cultural match between buyer and seller—and to drive optimum value for our clients.
-
Read More
It isn’t over until it’s over.
The process of selling a MedTech company is often a windy road that requires flexibility, creativity, and tenacity.
-
The process of selling a MedTech company is often a windy road that requires flexibility, creativity, and tenacity.
-
of sale transactions were negotiated versus auction process
-
of clients regardless of company status (including distressed sales) received offers to purchase
COMPANY SALE CALL TO ACTION
We have developed a one-page MedTech Valuation Inputs form, which when completed by you will provide us with the information we need to give you a range of expected market values for your company and a description of the type of buyers who are likely to value your company most highly.
Please provide your contact information and we will send the MedTech Valuation Inputs form along with a Non-Disclosure Agreement for your review.
Form on the sell page
"*" indicates required fields
Team & Reach
Our team of M&A and former MedTech executives have worked in the US, Europe, Israel, Japan and Taiwan and have extensive networks throughout those markets. Our US acquirers are often looking for entry into the most lucrative MedTech market in the world, the US market. Kinsella Group can serve as US seller by making that connection with a strong OUS buyer.